No Evidence of Adverse Effects of Proscar on Myasthenia Gravis
Based on available evidence, there is no documented interaction between Proscar (finasteride) and myasthenia gravis (MG), and finasteride does not appear on established lists of medications known to exacerbate MG.
Evidence Review
Drug Label Analysis
The FDA-approved Proscar label 1 provides comprehensive safety information but makes no mention of myasthenia gravis as a contraindication, precaution, or adverse effect. The mechanism of action—selective inhibition of Type II 5α-reductase to reduce dihydrotestosterone (DHT)—does not involve the neuromuscular junction, acetylcholine receptors, or acetylcholinesterase activity that are central to MG pathophysiology.
Myasthenia Gravis Drug Safety Literature
Multiple comprehensive reviews of medications that can trigger or worsen MG 2, 3, 4, 5 consistently identify specific drug classes as problematic:
- Neuromuscular blocking agents (most frequently implicated)
- Beta-blockers
- Fluoroquinolones and aminoglycoside antibiotics
- Macrolide antibiotics
- Magnesium (IV)
- D-penicillamine (immunological mechanism)
Finasteride is not mentioned in any of these reviews as a drug of concern for patients with MG.
Reported Finasteride Adverse Effects
One case report 6 documented finasteride-associated myalgia and elevated creatine kinase (hyperCKemia) in a patient without MG, which resolved upon drug discontinuation. This represents a distinct myopathic process unrelated to neuromuscular junction dysfunction characteristic of MG. The patient had no weakness or pigmenturia—features that would be expected if this were MG-related.
Clinical Implications
Proscar can be safely prescribed to patients with myasthenia gravis for treatment of benign prostatic hyperplasia (BPH). The drug's mechanism—hormonal modulation through 5α-reductase inhibition—does not interfere with:
- Acetylcholine release at the presynaptic terminal
- Nicotinic acetylcholine receptors at the postsynaptic membrane
- Acetylcholinesterase function
- Immune-mediated processes at the neuromuscular junction
Monitoring Considerations
While finasteride itself does not worsen MG, standard clinical vigilance applies:
- Monitor for any new muscle weakness when initiating any medication in MG patients, as individual responses can vary
- Distinguish myopathic symptoms (diffuse muscle pain, elevated CK) from myasthenic symptoms (fatigable weakness, fluctuating symptoms, ocular/bulbar involvement)
- Continue standard MG management including cholinesterase inhibitors and immunosuppressants as indicated
Common Pitfall to Avoid
Do not confuse the rare myalgia/hyperCKemia associated with finasteride 6 with MG exacerbation. These are mechanistically distinct conditions: myopathy involves muscle fiber damage (elevated CK, muscle pain), while MG involves impaired neuromuscular transmission (fatigable weakness, normal CK).